[go: up one dir, main page]

PE20220485A1 - Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos - Google Patents

Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos

Info

Publication number
PE20220485A1
PE20220485A1 PE2022000038A PE2022000038A PE20220485A1 PE 20220485 A1 PE20220485 A1 PE 20220485A1 PE 2022000038 A PE2022000038 A PE 2022000038A PE 2022000038 A PE2022000038 A PE 2022000038A PE 20220485 A1 PE20220485 A1 PE 20220485A1
Authority
PE
Peru
Prior art keywords
targeting agents
microtubule
peptide conjugates
therapeutics
alkyl
Prior art date
Application number
PE2022000038A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Johanna Marie Csengery
Robert John Maguire
Robert A Volkmann
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of PE20220485A1 publication Critical patent/PE20220485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de formula R2-L-R1 (Formula I) o una sal farmaceuticamente aceptable del mismo, caracterizado porque: R1 es un peptido capaz de suministrar selectivamente R2 L- a traves de una membrana que tiene un manto acido o hipoxico; R2 se selecciona a partir del grupo a), b), entre otros; L es -S-S-, -NA-CO-O-CR3R4-CR5R6-S-S-, entre otros; R3, R4, R5 y R6 son H, alquilo C1-4, alquenilo C1-4, arilo C6-10, cicloalquilo C3-10, heteroarilo de 5-10 miembros, heterocicloalquilo de 4-10 miembros, halo, entre otros; A es H o alquilo C1-4. Dichos conjugados peptidicos de agentes dirigidos a microtubulos tales como derivados de maitansinoide son utiles para el tratamiento de enfermedades tal como cancer.
PE2022000038A 2019-07-10 2020-07-09 Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos PE20220485A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19
PCT/US2020/041348 WO2021007402A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of microtubule-targeting agents as therapeutics

Publications (1)

Publication Number Publication Date
PE20220485A1 true PE20220485A1 (es) 2022-04-04

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000038A PE20220485A1 (es) 2019-07-10 2020-07-09 Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos

Country Status (19)

Country Link
US (2) US11555019B2 (es)
EP (1) EP3996749A1 (es)
JP (1) JP7675060B2 (es)
KR (1) KR20220051332A (es)
CN (1) CN114302744B (es)
AU (1) AU2020311925A1 (es)
BR (1) BR112022000297A2 (es)
CA (1) CA3146385A1 (es)
CL (1) CL2022000043A1 (es)
CO (1) CO2022001315A2 (es)
CR (1) CR20220057A (es)
EC (1) ECSP22010121A (es)
IL (1) IL289659B1 (es)
MX (1) MX2022000450A (es)
MY (1) MY209459A (es)
PE (1) PE20220485A1 (es)
PH (1) PH12022550037A1 (es)
TW (1) TW202116356A (es)
WO (1) WO2021007402A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007060A (es) 2018-01-05 2020-11-11 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
MX2023008146A (es) 2021-01-08 2023-07-24 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados.
PE20242180A1 (es) * 2021-11-17 2024-11-07 Cybrexa 4 Inc Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
TR199800127T1 (xx) 1995-08-02 1998-04-21 Newcastle University Ventures Limited Benzimidazol bile�ikleri.
WO1997041124A1 (en) 1996-04-26 1997-11-06 Daiichi Pharmaceutical Co., Ltd. Process for the preparation of tetrahydro-indolizines
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
EP1080732A4 (en) 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
AU765409B2 (en) 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
SK287338B6 (sk) 1999-01-11 2010-07-07 Agouron Pharmaceuticals, Inc. Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
WO2001041534A2 (en) 1999-12-13 2001-06-14 Eli Lilly And Company Pseudomycin phosphate prodrugs
KR20030009388A (ko) * 2000-03-15 2003-01-29 브리스톨-마이어스 스퀴브 파마 컴파니 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도
CA2415922A1 (en) 2000-07-13 2002-01-24 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compound
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
NZ534719A (en) 2002-03-01 2008-02-29 Univ Tulane Conjugates of therapeutic or cytotoxic agents and biologically active peptides
RU2312857C2 (ru) 2002-03-20 2007-12-20 Бристол-Маерс Сквибб Компани Фосфатные производные фтороксиндолов и способ лечения с их использованием
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ542695A (en) 2003-05-20 2009-04-30 Immunogen Inc Improved cytotoxic agents comprising new maytansinoids
NZ544989A (en) 2003-07-25 2009-10-30 Cancer Rec Tech Ltd Tricyclic PARP inhibitors
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
BRPI0417056A (pt) 2003-12-01 2007-02-06 Kudos Pharm Ltd inibidores de reparo de dano no dna para tratamento de cáncer
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
MX2007002461A (es) 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
MX2007003311A (es) 2004-09-22 2007-05-16 Pfizer Procedimiento para preparar inhibidores de poli (adp-ribosa) polimerasas.
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ES2539126T3 (es) 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
EP1846014B1 (en) 2005-01-18 2012-10-24 The Board of Governors for Higher Education State of Rhode Island and Providence Plantations Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
CA2597407C (en) 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
MX2007012817A (es) 2005-04-15 2007-12-12 Immunogen Inc Eliminacion de poblacion celular heterogenea o mezclada en tumores.
EP2662096A1 (en) 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
CN101370497B (zh) 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
CN101479295A (zh) 2006-05-04 2009-07-08 健泰科生物技术公司 涉及zpa多肽的方法和组合物
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
NZ583931A (en) 2007-08-17 2012-06-29 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
WO2011066418A1 (en) 2009-11-25 2011-06-03 Academia Sinica The tumor-selective anti-cancer prodrug bqc-g
KR20120127495A (ko) 2010-02-12 2012-11-21 화이자 인코포레이티드 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
CA3032185C (en) 2010-07-13 2021-08-03 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
AU2011289279B2 (en) 2010-08-13 2016-11-03 University Of Rhode Island Board Of Trustees Liposome compositions and methods of use thereof
MX2013005046A (es) 2010-11-03 2013-12-12 Immunogen Inc Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN115960111A (zh) 2012-10-11 2023-04-14 第一三共株式会社 抗体－药物偶联物
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
EP2911701A4 (en) 2012-10-23 2016-06-08 Univ Johns Hopkins Novel self-assembling drug amphiphiles and methods for synthesis and application
US9919059B2 (en) 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
CN105051032B (zh) 2013-01-03 2017-08-15 赛特瑞恩股份有限公司 抗体‑连接子‑药物偶联物、其制法及包含其的抗癌药物组合物
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
CN105917007A (zh) 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
SI3129063T1 (sl) 2014-04-10 2021-08-31 Daiichi Sankyo Company PROTI-HER3 konjugat zdravila s protitelescem
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
WO2016044234A1 (en) 2014-09-16 2016-03-24 Eric Tsao Anti-egfr antibody and uses of same
EP3954373A1 (en) 2014-10-07 2022-02-16 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
CN107592813A (zh) 2014-11-19 2018-01-16 伊缪诺金公司 用于制备细胞结合剂‑细胞毒性剂缀合物的方法
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
WO2017091544A1 (en) 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
US20200078468A1 (en) * 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
US20210283281A1 (en) 2016-07-29 2021-09-16 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
MX2019001905A (es) 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
WO2018057912A1 (en) * 2016-09-22 2018-03-29 Rhode Island Council On Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH -TRIGGERED POLYPEPTIDE
PL3546448T3 (pl) 2016-11-25 2022-09-05 Mabwell (shanghai) Bioscience Co., Ltd. Łącznik stanowiący dipodstawiony amid kwasu maleinowego dla koniugacji przeciwciało-lek oraz sposób jego wytwarzania i zastosowanie
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CA3066384A1 (en) 2017-06-09 2018-12-13 Rhode Island Council On Postsecondary Education Linked and other ph-triggered compounds
CN117838881A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
MX2020007060A (es) 2018-01-05 2020-11-11 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
EP3737383A4 (en) 2018-01-12 2021-12-15 Prolynx LLC SYNERGISTIC CANCER TREATMENT
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2020160009A1 (en) 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® targeted delivery of potent cytotoxic compounds
LT3946464T (lt) 2019-03-29 2022-11-10 Medimmune Limited Junginiai ir jų konjugatai
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
MX2023008146A (es) 2021-01-08 2023-07-24 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados.
CA3218253A1 (en) 2021-04-29 2022-11-03 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
PE20242180A1 (es) 2021-11-17 2024-11-07 Cybrexa 4 Inc Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos

Also Published As

Publication number Publication date
CR20220057A (es) 2022-07-19
CO2022001315A2 (es) 2022-05-10
WO2021007402A1 (en) 2021-01-14
JP7675060B2 (ja) 2025-05-12
PH12022550037A1 (en) 2023-04-12
US11555019B2 (en) 2023-01-17
TW202116356A (zh) 2021-05-01
IL289659B1 (en) 2026-01-01
ECSP22010121A (es) 2022-05-31
AU2020311925A1 (en) 2022-02-03
CN114302744A (zh) 2022-04-08
BR112022000297A2 (pt) 2022-03-15
US12234212B2 (en) 2025-02-25
IL289659A (en) 2022-03-01
MX2022000450A (es) 2022-04-25
MY209459A (en) 2025-07-09
JP2022541747A (ja) 2022-09-27
US20210009536A1 (en) 2021-01-14
US20240067616A1 (en) 2024-02-29
EP3996749A1 (en) 2022-05-18
KR20220051332A (ko) 2022-04-26
CL2022000043A1 (es) 2022-08-19
CN114302744B (zh) 2025-08-26
CA3146385A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
PE20220485A1 (es) Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos
PE20231081A1 (es) Derivados de quinoxalina como farmacos contra el cancer
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
BR112022012641A2 (pt) Compostos tricíclicos substituídos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR112283A1 (es) Uso de derivados de aminoalquilbenzotiazepina
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR127254A1 (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
PE20212329A1 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR074833A1 (es) Agentes lipopeptidicos antibacterianos para el tratamiento de infecciones con grampositivos
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
AR054272A1 (es) Derivados de 3- aminopirrilidinas tri, tetra - sustituidos
RU2010123895A (ru) Гетероциклические соединения
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
MX2022011240A (es) Azálidos de urea inmunomoduladores.
PE20241186A1 (es) Compuestos de cd73
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso